THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Bigtime losses, but cash still flows in

It’s a poorly kept secret: Biotechs rarely make money. But their potential keeps investment dollars flowing.

By Stephen Heuser
Globe Staff / May 6, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biotechnology proponents rarely talk about the fact that the industry loses huge quantities of money. According to a new report from accountants Ernst & Young, the public biotechnology companies in New England collectively lost $1.3 billion in 2006, the highest loss of any region in the country. (Full article: 921 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass